Navigation Links
New formula invented for microscope viewing, substitutes for federally controlled drug
Date:5/17/2013

Researchers at Rutgers, The State University of New Jersey, and City University of New York have invented a proprietary new formulation called VisikolTM that effectively clears organisms to be viewed under microscopes. Visikol can be used in place of chloral hydrate, which is one of the few high-quality clearing solutions currently available but which is tightly regulated by the Drug Enforcement Administration (DEA) due to its use as a narcotic.

Clearing solutions, or clearing agents, are vital for viewing organisms under a microscope. Without them, microscope images become refracted and scattered, impairing the clarity of vision. Clearing solutions are used to identify specimens and examine their anatomy by "clearing" them, increasing the transparency of the specimen by rendering some components of a specimen invisible in order to better view other components of interest.

One of the most common clearing solutions is chloral hydrate, which is used for everything from studying plant organelles to authenticating herbal plant species for medicinal purposes. Its popularity in the research community, government, and industry stems from its high refractive index, which allows a high magnitude of light to pass through the medium and make specimens crystal clear under the microscope.

However, chloral hydrate is difficult and expensive to obtain, as it is regulated by the DEA as a Schedule IV controlled substance. Chloral hydrate is prescribed medically as a sedative, depressant, pain reliever, and hypnotic, and overdoses can lead to serious health issues, including fatal heart conditions. Chloral hydrate has also found use as an illicit drug, and has been used in sexual assaults. Thus, possession of chloral hydrate requires costly, annual permits and time-consuming paperwork. Despite its advantages for research and industry, chloral hydrate is an impractical, and sometimes impossible, choice for scientists.

To replace c
'/>"/>

Contact: Beth Parada
apps@botany.org
American Journal of Botany
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study shows botanical formula fights prostate cancer
2. Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use
3. Hazelnuts improve infant formula
4. Liquid glucagon formulation discovered for potential use in artificial pancreas systems
5. Maths formula leads researchers to source of pollution
6. Breast milk promotes a different gut flora growth than infant formulas
7. UC Riverside developing biofuel formulations for California
8. New, cost-cutting approach to formulating pest-killing fungi
9. Human eye inspires clog-free ink jet printer invented by MU researcher
10. Beyond the microscope: Identifying specific cancers using molecular analysis
11. Nature: Microscope looks into cells of living fish
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Genomic research could help doctors better target a drug widely ... by Genomic Health Inc. (Nasdaq: GHDX) and the Translational Genomics ... in colon cancer. It is used in early disease, following ... is also used in advanced disease to slow progression of ...
... were initiated in 1971 and have become a leading ... enzyme technology and biocatalysis, putting an emphasis on emerging ... aspects. The proposed scope and thrust of the ... on new developments in fields including protein design and ...
... report that they are the first to show in molecular ... split up via gene duplication to pursue their ... Proceedings of the National Academy of Sciences , validates a ... also confirms the ancestry of a family of "antifreeze proteins" ...
Cached Biology News:TGen and Genomic Health Inc. discover genes affecting cancer drug 2Researchers show how 1 gene becomes 2 (with different functions) 2Researchers show how 1 gene becomes 2 (with different functions) 3
(Date:7/28/2015)... YORK , July 28, 2015 Tauriga ... a diversified life sciences company, today announced that its ... shares of common stock of the Company from 1,000,000,000 ... on July 27, 2015 at the Law Offices of ...  At the Special Meeting, there were 480,655,929 shares of ...
(Date:7/28/2015)... 28, 2015  Moerae Matrix Inc. announced today ... trial with MMI-0100, a first-in-class inhibitor of MAPKAP ... pulmonary disorders characterized by inflammation and fibrosis.  The ... , is a double-blind, two-way cross-over design ... and tolerability of MMI-0100 when given via inhalation ...
(Date:7/28/2015)... OF PRUSSIA, Pa. , July 28, 2015 /PRNewswire/ ... U.S. Food and Drug Administration has accepted for review ... investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment ... met all primary endpoints. Hemophilia ... deficient or defective factor VIII; nearly all affected patients ...
(Date:7/28/2015)... RESEARCH TRIANGLE PARK, N.C., July 28, 2015  United ... its financial results for the second quarter ended ... nearly 300% as compared to the second quarter ... said Roger Jeffs, Ph.D., United Therapeutics, President and ... was due to an increase in the number ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... , ATLANTA, Oct. 6 CryoLife, Inc., ... and cardiovascular tissue processing company, today announced that it has ... and Drug Administration (FDA) for its CryoValve® SG aortic human ... in obtaining a Humanitarian Device Exemption (HDE) for the CryoValve ...
... , ROCKVILLE, Md., Oct. 6 Novavax, Inc. (Nasdaq: ... Rahul Singhvi, President and CEO of Novavax, will be making ... October 7th, 2009 at the Palais des Congres de Lyon, ... ,Innovative Approaches to RSV vaccine development and VLP based vaccines, ...
... Oct. 6 State, county and local government leaders ... REGN ) and BioMed Realty Trust, Inc. (NYSE: ... new 229,000 square foot corporate headquarters and research facility ... New York. Featured speakers at the ceremony were Leonard ...
Cached Biology Technology:CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 2CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 3CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 4Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 2Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 3Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 4Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 5
... 1 outflow Single-cell and patch delivery ... solution change Very small dead volume , ... 360, 250 and 100 micron delivery tips ... micromanipulator Available in 4, 8, and 16 ...
... Racks are ideal for storage and transport ... polypropylene racks withstand extreme temperatures, making them ... may also be autoclaved for use in ... side accommodates 0.5ml microcentrifuge tubes, the other ...
... consists of universal lysis buffer, PCR mix, ... 100 25 l volume PCR reactions. This ... negative or positive rod and coccus bacteria, ... Cereus, Staphylococcus Aureus, Streptococcus Agalactiae, and etc. ...
... BacVector Insect Cell Medium is optimized for ... Insect Cells. In this protein-free medium, Sf9 ... * 107 cells/ml with viabilities above 95%. ... assays, where color from X-gluc staining of ...
Biology Products: